Medicenna Therapeutics Presents Promising Preclinical Data on MDNA223 at AACR Special Conference

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, recently unveiled new preclinical data on MDNA223, an anti-PD1-IL-2 BiSKIT, at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held in Toronto, Canada. The presentation showcased the potential of Medicenna’s Superkines and the versatility of their next-generation BiSKITs platform in tackling “cold” tumors, which have been a challenge for immunotherapy.

Fahar Merchant, Ph.D., President and CEO of Medicenna, expressed excitement about the results, stating that the dual-functioning BiSKIT candidates, like MDNA223, have demonstrated increased potency and selectivity in inducing superior CD8+ T cell responses against tumor cells. These findings highlight the potential of MDNA223 as a monotherapy or in combination with other treatment modalities, including cell-based therapies, to improve patient outcomes.

MDNA223 is a fusion of Medicenna’s IL-2 Superkine with an anti-PD1 antibody, designed to maximize the anti-tumor response by simultaneously stimulating the IL-2R pathway and blocking PD1 checkpoint on the same effector immune cell. The preclinical data presented at the conference demonstrated that MDNA223 BiSKIT showed promising results, including enhanced tumor cell killing, improved immune cell activation, and prevention of immune cell exhaustion.

Medicenna’s BiSKIT platform has the potential to deliver effective therapy to challenging-to-treat “cold” tumors. The company’s commitment to developing novel immunotherapies, such as MDNA223, showcases their dedication to advancing cancer treatment options.

For more information on the preclinical data presented, copies of the poster can be found on Medicenna’s website under the “Events and Presentations” page.

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4, and IL-13 Superkines. Their innovative approach, including the long-acting IL-2 Superkine MDNA11 and the IL-4 Empowered Superkine bizaxofusp, has shown promise in clinical trials for various cancers.

In conclusion, Medicenna’s presentation at the AACR Special Conference highlights their commitment to advancing immunotherapy and their potential to provide effective treatment options for patients with challenging-to-treat tumors.